Compare ARK Genomic Revolution ETF (ARKG) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Norfolk Southern Corporation — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Norfolk Southern Corporation trades at $328.02 (market cap $73.55B). The key difference: Norfolk Southern Corporation pays a 1.65% dividend while ARK Genomic Revolution ETF pays none, and Norfolk Southern Corporation is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | NSC | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $327.47 |
52-Week Low | $23.09 | $259.49 |
Market Cap | — | $73.55B |
Enterprise Value | — | $89.31B |
Dividend Yield | — | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Norfolk Southern (NSC) trades at $327.47, up 1.14% with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.65 exceeding expectations of $2.49. Valuation metrics include a P/E of 27.59 and ROE of 17.6%, while analyst consensus targets $342.67. Recent developments include the pending merger with Union Pacific and upcoming Q2 2026 earnings on July 23, 2026.
NSC presents a favorable investment case with strong profitability and merger potential, though regulatory scrutiny and rich valuations pose risks. The stock's proximity to 52-week highs suggests limited near-term upside, but long-term growth prospects remain solid if merger approvals proceed smoothly and operational efficiency improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
